Exelixis unveils additional data on Cabometyx for neuroendocrine tumors [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
Results from the phase 3 CABINET trial, presented at the European Society for Medical Oncology Congress, showed that at a median follow-up of 13.8 months, median progression-free survival in the pNET cohort was 13.8 months for Cabometyx versus 4.4 months for placebo. In the other cohort, at a median follow-up of 10.2 months, median PFS was, respectively, 8.4 months and 3.9 months. Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date of April 3, 2025 for the supplemental New Drug Application. In a separate ESMO presentation, Exelixis said that new data from the phase 3 CONTACT-02 trial examining Cabometyx (cabozantinib) in combination with Roche's ( OTCQX:RHHBY ) Tecentriq (atezolizumab) showed that in patients with metastatic castration-resistant prostate cancer, at a median follow-up of 24 months, a numerical but not statistically significant improvement in overall survival favored the combination compared t
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis, Inc. (NASDAQ: EXEL) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $29.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $30.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss [Yahoo! Finance]Yahoo! Finance
- Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors [Financial Post (Toronto, Ontario, Canada)]Financial Post
EXEL
Earnings
- 8/6/24 - Beat
EXEL
Sec Filings
- 8/28/24 - Form 4
- 8/16/24 - Form 4
- 8/15/24 - Form 4
- EXEL's page on the SEC website